Minerva Neurosciences Inc
NERV
查看详细走势图
4.040USD
+0.170+4.39%
收盘 12/19, 16:00（美东）报价延迟15分钟
28.25M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.39%
5天
+4.12%
1月
-6.91%
6月
+128.25%
今年开始到现在
+81.85%
1年
+87.04%
查看详细走势图
TradingKey Minerva Neurosciences Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Minerva Neurosciences Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名112/404位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价4.50。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Minerva Neurosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
持有
评级
4.500
目标均价
+16.28%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Minerva Neurosciences Inc亮点
亮点风险
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
业绩转盈
公司业绩转盈，最新年度盈利美元
估值低估
公司最新PE估值-2.18，处于3年历史低位
机构减仓
最新机构持股1.98M股，环比减少8.16%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值116.50K
活跃度增加
近期活跃度增加，过去20天平均换手率0.02
Minerva Neurosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Minerva Neurosciences Inc简介
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
公司代码NERV
公司Minerva Neurosciences Inc
CEOLuthringer (Remy)
网址https://www.minervaneurosciences.com/
常见问题
Minerva Neurosciences Inc(NERV)的当前股价是多少？
Minerva Neurosciences Inc(NERV)的当前股价是 4.040。
Minerva Neurosciences Inc的股票代码是什么？
Minerva Neurosciences Inc的股票代码是NERV。
Minerva Neurosciences Inc股票的52周最高点是多少？
Minerva Neurosciences Inc股票的52周最高点是12.460。
Minerva Neurosciences Inc股票的52周最低点是多少？
Minerva Neurosciences Inc股票的52周最低点是1.150。
Minerva Neurosciences Inc的市值是多少？
Minerva Neurosciences Inc的市值是28.25M。
Minerva Neurosciences Inc的净利润是多少？
Minerva Neurosciences Inc的净利润为1.44M。
现在Minerva Neurosciences Inc(NERV)的股票是买入、持有还是卖出？
根据分析师评级，Minerva Neurosciences Inc(NERV)的总体评级为持有，目标价格为4.500。
Minerva Neurosciences Inc(NERV)股票的每股收益（EPS TTM）是多少
Minerva Neurosciences Inc(NERV)股票的每股收益（EPS TTM）是-1.853。
相关品种
